Welcome to our dedicated page for Fulgent Genetics news (Ticker: FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics stock.
Fulgent Genetics, Inc. reports developments across a laboratory services business and a therapeutic development business. Its laboratory operations provide technical laboratory and genetic testing services, with professional interpretation of results by licensed physicians. Its therapeutic development work focuses on cancer drug candidates using a nanoencapsulation and targeted therapy platform designed for new and existing oncology drugs.
Recurring company news includes operating and financial results, revenue guidance, stock repurchase activity, laboratory-services partnerships, and precision medicine testing initiatives. Clinical updates also cover oncology programs such as FID-007 and FID-022, including disclosures related to head and neck cancer research and presentations at oncology meetings.
Fulgent (NASDAQ: FLGT) announced a rapid oral full abstract presentation at ASCO 2026 for Phase 2 trial FID-007 plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma.
Interim data in 42 patients showed 60% ORR, 7.2-month median PFS, and mainly grade 1–2 TRAEs, with some grade 3–4 events and one grade 5 pneumonia.
Foundation Medicine announced the launch of FoundationOne PGx, a pharmacogenetic test for oncology available in the United States through an expanded partnership with Fulgent Genetics (NASDAQ: FLGT) on May 4, 2026. The oncology-relevant panel covers genes tied to drug metabolism and actionable guidelines.
The panel includes CYP2C19, CYP2C9, CYP2D6, DPYD, G6PD, NUDT15, TPMT, UGT1A1 and UGT1A4 to inform dosing, anticipate toxicity, and reduce adverse drug reactions across chemotherapy, targeted therapies, and supportive care.
Fulgent Genetics (NASDAQ: FLGT) reported Q1 2026 results: revenue $71.1M, GAAP loss $24.8M ($(0.80)/share), Non‑GAAP loss $11.0M ( $(0.36)/share), and adjusted EBITDA loss $15.2M. The company repurchased ~2.6M shares for $40.1M in Q1 and ended the quarter with $604.7M in cash and equivalents (excluding an anticipated ~$106M tax refund). Full‑year 2026 revenue guidance is maintained at ~$350.0M; updated Non‑GAAP loss guidance is ~$46.0M or $(1.59)/share, and projected year‑end cash of ~$636.0M (assumptions apply).
Fulgent (NASDAQ: FLGT) announced its abstract on FID-007 plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) was selected for a Rapid Oral Abstract Session at ASCO 2026.
Presentation: Monday, June 1, 2026, 4:30–6:00pm CDT, hall D1, McCormick Place; Abstract #6020. The Phase 2 study (NCT06332092) evaluates dosing, pharmacokinetics, safety, and tolerability after PD-L1 inhibitor progression. The abstract posts on May 21, 2026; full slides will be on Fulgent investor relations at session start.
Fulgent (NASDAQ: FLGT) will release its first quarter 2026 financial results before the market opens on Friday, May 1, 2026. Management will host a conference call and live audio webcast at 8:30 AM ET (5:30 AM PT) the same day to discuss results and take questions. An audio replay will be available on the company Investor Relations website.
Fulgent Genetics (NASDAQ: FLGT) completed the acquisition of Bako Diagnostics and StrataDx on March 17, 2026. The company acquired certain assets of Bako and purchased StrataDx for a combined cash purchase price of approximately $56.9 million, subject to post-closing adjustments.
The acquisitions add a premier pathology laboratory and a premier dermatopathology laboratory to Fulgent's laboratory services businesses. Financial and legal advisors to both sides were disclosed.
Fulgent Genetics (NASDAQ: FLGT) reported Q4 2025 revenue of $83.3M (+9% YoY) and FY 2025 revenue of $322.7M (+14% YoY). GAAP loss for FY was $60.5M (loss of $1.97/share); non-GAAP income was $13.2M ($0.42/share). Cash and equivalents totaled $705.5M excluding an expected ~$106.3M tax refund. Management flagged a large customer moving volume in-house and provided 2026 guidance: revenue ~$350M, non-GAAP loss ~$(1.45) per share, and pro forma cash ~$685M, assuming a ~$56M acquisition spend for Bako and Strata Dx.
Fulgent Genetics (NASDAQ: FLGT) will release fourth quarter and full year 2025 financial results before the market opens on Friday, February 27, 2026.
Management will host a conference call the same day at 8:30 AM ET (5:30 AM PT) with a live audio webcast and an audio replay available on the company Investor Relations website.
Fulgent Genetics (NASDAQ: FLGT) agreed to acquire selected assets of Bako Diagnostics and to acquire StrataDx for a combined purchase price of approximately $55.5 million, payable from cash on hand. The deals are expected to close in the first half of 2026, subject to customary closing conditions including regulatory approvals.
The acquisitions add anatomic and dermatopathology services, proprietary PCR tests, CLIA/CAP/NY-certified labs in Georgia and Massachusetts, and a national salesforce that will nearly double Fulgent’s pathology sales team, while enabling further use of Fulgent’s Eziopath image management and AI tools.
Fulgent Genetics (NASDAQ: FLGT) said members of management will present at two investor conferences in November and December 2025. Presentations are scheduled for the UBS Global Healthcare Conference on Monday, November 10, 2025 at 5:00 PM ET and the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 11:00 AM ET.
Live webcasts and replays will be available on the company's Investor Relations website at ir.fulgentgenetics.com, with replays posted about one hour after each event ends.